San Diego-dependent Viking Therapeutics marked by itself as a serious competitor within the weight loss drug current market in February following revealing promising data from the mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when specified like a weekly injection and in March the c